Merops Switch to
Inhibitors

Peptidase

Family Clan SEARCHES BLAST
MEROPS SUBMISSIONS

Other
information

Literature for peptidase M14.009: carboxypeptidase B2

Summary Gene structure Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Inhibitors Pharma

(Topics flags: A Assay, S Structure, T Target, P Specificity, K Knockout, E Expression, V Review, M Mutation, I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

    2025
  1. Maruo,K., Tsubota,M., Tajima,K., Matsunaga,H., Sekiguchi,F., Minami,T., Ito,A., Tomono,Y., Nishibori,M. and Kawabata,A.
    Thrombomodulin-Induced Prevention of Peripheral Neuropathy in Oxaliplatin-Treated Mice Involves Complement C5a Inactivation and PAR1 Activation in Addition To HMGB1 Degradation
    J Neuroimmune Pharmacol (2025) 20, 100-100. PubMed  Europe PubMed DOI
    2. 2023
  2. Aksakal,A., Kilic,A.F., Afsin,D.E., Baygutalp,N.K. and Kerget,B.
    Evaluation of the relationship between TAFI level and prognosis in COVID-19 patients
    Eur Rev Med Pharmacol Sci (2023) 27, 4764-4771. PubMed  Europe PubMed DOI
    3. 2021
  3. Schaffner,A.P., Sansilvestri-Morel,P., Despaux,N., Ruano,E., Persigand,T., Rupin,A., Mennecier,P., Vallez,M.O., Raimbaud,E., Desos,P. and Gloanec,P.
    Phosphinanes and Azaphosphinanes as Potent and Selective Inhibitors of Activated Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa)
    J Med Chem (2021) 64, 3897-3910. PubMed  Europe PubMed DOI
  4. Sillen,M. and Declerck,P.J.
    Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review
    Int J Mol Sci (2021) 22 PubMed  Europe PubMed DOI  PMC  EPMC
  5. Wheeler,J.X., Thelwell,C., Rigsby,P. and Whiting,G.
    Quantitation of thrombin-activatable fibrinolysis inhibitor in human plasma by isotope dilution mass spectrometry
    Anal Biochem (2021) , 114413-114413. PubMed  Europe PubMed DOI
  6. Zhou,Q., Zhao,L., Shao,Z., Declerck,P., Leung,L.L.K. and Morser,J.
    Both plasma basic carboxypeptidases, carboxypeptidase B2 and carboxypeptidase N, regulate vascular leakage activity in mice
    J Thromb Haemost (2021) 20, 238-244. PubMed  Europe PubMed DOI
    7. 2020
  7. Mertens,J.C., Boisseau,W., Leenaerts,D., Di Meglio,L., Loyau,S., Lambeir,A.M., Ducroux,C., Jandrot-Perrus,M., Michel,J.B., Mazighi,M., Hendriks,D. and Desilles,J.P.
    Selective inhibition of carboxypeptidase U may reduce microvascular thrombosis in rat experimental stroke
    J Thromb Haemost (2020) PubMed  Europe PubMed DOI  I
  8. Minami,T., Takeda,M., Sata,M., Kato,H., Yano,K., Sakai,T., Tsujita,R., Kawasaki,K. and Ito,A.
    Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity
    Eur J Pharmacol (2020) 880, 173196-173196. PubMed  Europe PubMed DOI
  9. Nougier,C., Benoit,R., Simon,M., Desmurs-Clavel,H., Marcotte,G., Argaud,L., David,J.S., Bonnet,A., Negrier,C. and Dargaud,Y.
    Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis
    J Thromb Haemost (2020) PubMed  Europe PubMed DOI  PMC  EPMC
  10. Pedersen,N.B., Stolberg,C.R., Mundbjerg,L.H., Juhl,C.B., Gram,B., Funch-Jensen,P., de Maat,M.P.M., Munster,A.B. and Bladbjerg,E.M.
    Reductions in plasmin inhibitor and fibrinogen predict the improved fibrin clot lysis 6 months after obesity surgery
    Clin Obes (2020) , e12397-e12397. PubMed  Europe PubMed DOI
  11. Sanda,T., Yoshimura,M., Hyodo,K., Ishii,H. and Yamashita,T.
    Effects of Long-term Thrombin Inhibition (Dabigatran Etexilate) on Spontaneous Thrombolytic Activity during the Progression of Atherosclerosis in ApoE(-/-)-LDLR(-/-) Double-Knockout Mice
    Korean Circ J (2020) 50, 804-816. PubMed  Europe PubMed DOI  I
  12. Suzuki,Y., Sano,H., Mochizuki,L., Honkura,N. and Urano,T.
    Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system
    Blood Adv (2020) 4, 5501-5511. PubMed  Europe PubMed DOI  PMC  EPMC
    13. 2018
  13. Arauz,A., Arguelles,N., Jara,A., Guerrero,J. and Barboza,M.A.
    Thrombin-activatable fibrinolysis inhibitor polymorphisms and cerebral venous thrombosis in Mexican Mestizo patients
    Clin Appl Thromb Hemost (2018) 24, 1291-1296. PubMed  Europe PubMed DOI  M
  14. ElDanasori,N., Abulata,N., Shaheen,I.A., Elgendy,A.M. and El-Khayat,W.
    Thrombin-activatable fibrinolysis inhibitor gene polymorphism (TAFI1040C/T) in women with recurrent spontaneous abortion
    Clin Appl Thromb Hemost (2018) 24, 532-535. PubMed  Europe PubMed DOI  M
  15. Ito,Y., Noguchi,K., Morishima,Y. and Yamaguchi,K.
    Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor
    Blood Coagul Fibrinolysis (2018) 29, 314-321. PubMed  Europe PubMed DOI  K  I
  16. Itoh,T., Yoshimoto,N., Hirano,Y. and Yamamoto,K.
    Structural basis for the selective inhibition of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) by a selenium-containing inhibitor with chloro-aminopyridine as a basic group
    Bioorg Med Chem Lett (2018) 28, 2256-2260. PubMed  Europe PubMed DOI  S  I
  17. Leenaerts,D., Loyau,S., Mertens,J.C., Boisseau,W., Michel,J.B., Lambeir,A.M., Jandrot-Perrus,M. and Hendriks,D.
    Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different in vitro models
    J Thromb Haemost (2018) 16, 2057-2069. PubMed  Europe PubMed DOI  I
  18. Leung,L.L.K. and Morser,J.
    Carboxypeptidase B2 and carboxypeptidase N in the cross-talk between coagulation, thrombosis, inflammation and innate immunity
    J Thromb Haemost (2018) PubMed  Europe PubMed DOI
  19. Morser,J., Shao,Z., Nishimura,T., Zhou,Q., Zhao,L., Higgins,J. and Leung,L.L.K.
    Carboxypeptidase B2 and N play different roles in regulation of activated complements C3a and C5a in mice
    J Thromb Haemost (2018) 16, 991-1002. PubMed  Europe PubMed DOI  K
    20. 2017
  20. Gurewich,V. and Pannell,R.
    A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects: Comment
    J Thromb Haemost (2017) 15, 2080-2081. PubMed  Europe PubMed DOI  I
  21. Leenaerts,D., Aernouts,J., Van der Veken,P., Sim,Y., Lambeir,A.M. and Hendriks,D.
    Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis
    Thromb Haemost (2017) 117, 1498-1508. PubMed  Europe PubMed DOI
  22. Zhou,J., Kochan,J., Yin,O., Warren,V., Zamora,C., Atiee,G., Pav,J., Orihashi,Y., Vashi,V. and Dishy,V.
    A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects
    J Thromb Haemost (2017) 15, 961-971. PubMed  Europe PubMed DOI  I
    23. 2016
  23. Bazzi,Z.A., Lanoue,D., El-Youssef,M., Romagnuolo,R., Tubman,J., Cavallo-Medved,D., Porter,L.A. and Boffa,M.B.
    Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis
    BMC Cancer (2016) 16, 328-328. PubMed  Europe PubMed DOI  PMC  EPMC
  24. Denorme,F., Wyseure,T., Peeters,M., Vandeputte,N., Gils,A., Deckmyn,H., Vanhoorelbeke,K., Declerck,P.J. and De Meyer,S.F.
    Inhibition of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 reduces ischemic brain damage in mice
    Stroke (2016) 47, 2419-2422. PubMed  Europe PubMed DOI
  25. Gurewich,V. and Pannell,R.
    Structure-function relationships in thrombin-activatable fibrinolysis inhibitor: comment
    J Thromb Haemost (2016) 14, 1899-1900. PubMed  Europe PubMed DOI
  26. Halland,N., Czech,J., Czechtizky,W., Evers,A., Follmann,M., Kohlmann,M., Schreuder,H.A. and Kallus,C.
    Sulfamide as zinc binding motif in small molecule inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa)
    J Med Chem (2016) 59, 9567-9573. PubMed  Europe PubMed DOI  S  I
  27. Plug,T. and Meijers,J.C.
    Structure-function relationships in thrombin-activatable fibrinolysis inhibitor
    J Thromb Haemost (2016) 14, 633-644. PubMed  Europe PubMed DOI  V
  28. Schreuder,H., Liesum,A., Lonze,P., Stump,H., Hoffmann,H., Schiell,M., Kurz,M., Toti,L., Bauer,A., Kallus,C., Klemke-Jahn,C., Czech,J., Kramer,D., Enke,H., Niedermeyer,T.H., Morrison,V., Kumar,V. and Bronstrup,M.
    Isolation, co-crystallization and structure-based characterization of anabaenopeptins as highly potent inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa)
    Sci Rep (2016) 6, 32958-32958. PubMed  Europe PubMed DOI  PMC  EPMC  I
  29. Tawara,S., Sakai,T. and Matsuzaki,O.
    Anti-inflammatory and anti-fibrinolytic effects of thrombomodulin alfa through carboxypeptidase B2 in the presence of thrombin
    Thromb Res (2016) 147, 72-79. PubMed  Europe PubMed DOI
  30. Zhou,X., Weeks,S.D., Ameloot,P., Callewaert,N., Strelkov,S.V. and Declerck,P.J.
    Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity
    J Thromb Haemost (2016) 14, 1629-1638. PubMed  Europe PubMed DOI  I
    31. 2015
  31. Atkinson,J.M., Pullen,N., Da Silva-Lodge,M., Williams,L. and Johnson,T.S.
    Inhibition of thrombin-activated fibrinolysis inhibitor increases survival in experimental kidney fibrosis
    J Am Soc Nephrol (2015) 26, 1925-1937. PubMed  Europe PubMed DOI  I
  32. Halland,N., Bronstrup,M., Czech,J., Czechtizky,W., Evers,A., Follmann,M., Kohlmann,M., Schiell,M., Kurz,M., Schreuder,H.A. and Kallus,C.
    Novel small molecule inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa) from natural product anabaenopeptin
    J Med Chem (2015) 58, 4839-4844. PubMed  Europe PubMed DOI  I
  33. Plug,T. and Meijers,J.C.M.
    New clues regarding the mysterious mechanism of activated thrombin-activatable fibrinolysis inhibitor self-destruction
    J Thromb Haemost (2015) 13, 1081-1083. PubMed  Europe PubMed DOI
  34. Plug,T., Marquart,J.A., Marx,P.F. and Meijers,J.C.
    Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides
    J Thromb Haemost (2015) 13, 2093-2101. PubMed  Europe PubMed DOI
  35. Shao,Z., Nishimura,T., Leung,L.L. and Morser,J.
    Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model
    J Thromb Haemost (2015) 13, 1090-1102. PubMed  Europe PubMed DOI  K
  36. Zheng,C., Li,X., Kong,C., Ke,S., Peng,C., Cui,T., Gao,M., Zhou,Y., Guo,W., Huang,L., Petersen,R.B. and Huang,K.
    Effect of single nucleotide polymorphism in thrombin-activatable fibrinolysis inhibitor on the risk of diabetic macrovascular disease
    Blood Coagul Fibrinolysis (2015) 26, 185-190. PubMed  Europe PubMed DOI  M
  37. Zhou,X. and Declerck,P.J.
    Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation
    J Thromb Haemost (2015) 13, 1084-1089. PubMed  Europe PubMed DOI
    38. 2014
  38. Brink,M., Dahlen,A., Olsson,T., Polla,M. and Svensson,T.
    Design and synthesis of conformationally restricted inhibitors of active thrombin activatable fibrinolysis inhibitor (TAFIa)
    Bioorg Med Chem (2014) 22, 2261-2268. PubMed  Europe PubMed DOI  S  I
  39. He,F.-M., Pan,J.-G., Zhao,X.-Y., Yuan,H., Mou,X. and Chen,Y.-S.
    Correlation between C1040T and G753A polymorphisms in the gene encoding region of thrombin-activatable fibrinolysis inhibitor and cerebral infarction
    Chin J Cerebrovasc Dis (2014) 11, 347-353. DOI  M
  40. Kovacs,A., Szabo,L., Longstaff,C., Tenekedjiev,K., Machovich,R. and Kolev,K.
    Ambivalent roles of carboxypeptidase B in the lytic susceptibility of fibrin
    Thromb Res (2014) 133, 80-87. PubMed  Europe PubMed DOI
  41. Lepus,C.M., Song,J.J., Wang,Q., Wagner,C.A., Lindstrom,T.M., Chu,C.R., Sokolove,J., Leung,L.L. and Robinson,W.H.
    Brief report: carboxypeptidase B serves as a protective mediator in osteoarthritis
    Arthritis Rheum (2014) 66, 101-106. PubMed  Europe PubMed DOI
  42. Philippou,H.
    Thrombin activatable fibrinolysis inhibitor (TAFI): More complex when it meets the clot
    Thromb Res (2014) 133, 1-2. PubMed  Europe PubMed DOI
  43. Plug,T., Kramer,G. and Meijers,J.C.
    A role for arginine-12 in thrombin-thrombomodulin-mediated activation of thrombin-activatable fibrinolysis inhibitor
    J Thromb Haemost (2014) 12, 1717-1725. PubMed  Europe PubMed DOI
  44. Santos,I.R., Fernandes,A.P., Carvalho,M.G., Sousa,M.O., Ferreira,C.N. and Gomes,K.B.
    Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects
    Clin Chim Acta (2014) 433, 76-83. PubMed  Europe PubMed DOI  M
  45. Shi,J., Zhi,P., Chen,J., Wu,P. and Tan,S.
    Genetic variations in the thrombin-activatable fibrinolysis inhibitor gene and risk of cardiovascular disease: a systematic review and meta-analysis
    Thromb Res (2014) 134, 610-616. PubMed  Europe PubMed DOI  M
    46. 2013
  46. Chengwei,X., Xiaoli,M., Yuan,Z., Li,P., Shengjiang,W., Chao,Y. and Yunshan,W.
    Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer
    Blood Coagul Fibrinolysis (2013) 24, 698-703. PubMed  Europe PubMed DOI  M
  47. Fernandez,D., Pallares,I., Covaleda,G., Aviles,F.X. and Vendrell,J.
    Metallocarboxypeptidases and their Inhibitors: Recent Developments in Biomedically Relevant Protein and Organic Ligands
    Curr Med Chem (2013) 20, 1595-1608. PubMed  Europe PubMed  V  S  I
  48. Foley,J.H., Kim,P.Y., Mutch,N.J. and Gils,A.
    Insights into thrombin activatable fibrinolysis inhibitor function and regulation
    J Thromb Haemost (2013) 11 Suppl 1, 306-315. PubMed  Europe PubMed DOI
  49. Garand,M., Lin,J.H., Zagorac,B., Koschinsky,M.L. and Boffa,M.B.
    Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone
    Blood Coagul Fibrinolysis (2013) 24, 393-404. PubMed  Europe PubMed DOI
  50. Vercauteren,E., Gils,A. and Declerck,P.J.
    Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis
    Semin Thromb Hemost (2013) 39, 365-372. PubMed  Europe PubMed DOI  T
  51. Woodman,I.
    Osteoarthritis: carboxypeptidase B inhibits complement and cartilage loss
    Nat Rev Rheumatol (2013) 9, 697-697. PubMed  Europe PubMed DOI
    52. 2012
  52. Colucci,M. and Semeraro,N.
    Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation
    Thromb Res (2012) 129, 314-319. PubMed  Europe PubMed DOI
  53. Fujiwara,A., Taguchi,O., Takagi,T., D'Alessandro-Gabazza,C.N., Boveda-Ruiz,D., Toda,M., Yasukawa,A., Matsushima,Y., Miyake,Y., Kobayashi,H., Kobayashi,T., Gil-Bernabe,P., Naito,M., Yoshida,M., Morser,J., Takei,Y. and Gabazza,E.C.
    Role of thrombin-activatable fibrinolysis inhibitor in allergic bronchial asthma
    Lung (2012) 190, 189-198. PubMed  Europe PubMed DOI  K
  54. Hendriks,D.F.
    Carboxypeptidase U
    [ISSN:978-0-12-407744-7] (2012) 3, 1321-1324. DOI
  55. Mishra,N., Buelens,K., Theyskens,S., Compernolle,G., Gils,A. and Declerck,P.J.
    Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysis
    J Thromb Haemost (2012) 10, 1091-1099. PubMed  Europe PubMed DOI
  56. Xu,C.W., Wu,X.B., Ma,X.L., Wang,Y.S., Zhang,B.C., Zhao,J.J., Wang,Z.J. and Chen,J.
    Genetic variation in thrombin-activatable fibrinolysis inhibitor is associated with the risk of diabetic nephropathy
    J Endocrinol Invest (2012) 35, 620-624. PubMed  Europe PubMed DOI  M
  57. Yoshimoto,N., Sasaki,T., Sugimoto,K., Ishii,H. and Yamamoto,K.
    Design and characterization of a selenium-containing inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa), a zinc-containing metalloprotease
    J Med Chem (2012) 55, 7696-7705. PubMed  Europe PubMed DOI  I
    58. 2011
  58. Declerck,P.J.
    Thrombin activatable fibrinolysis inhibitor
    Hamostaseologie (2011) 31, 165-173. PubMed  Europe PubMed DOI  V
  59. Foley,J.H., Cook,P.F. and Nesheim,M.E.
    Kinetics of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)-catalyzed cleavage of C-terminal lysine residues of fibrin degradation products and removal of plasminogen-binding sites
    J Biol Chem (2011) 286, 19280-19286. PubMed  Europe PubMed DOI  P
  60. Heylen,E., Willemse,J.L. and Hendriks,D.F.
    Comparative study of commercially available procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) assays
    J Thromb Haemost (2011) 9, 1407-1409. PubMed  Europe PubMed DOI  A
  61. Heylen,E., Willemse,J. and Hendriks,D.
    An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis
    Front Biosci (2011) 16, 2427-2450. PubMed  Europe PubMed DOI  V
  62. Mishra,N., Vercauteren,E., Develter,J., Bammens,R., Declerck,P.J. and Gils,A.
    Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms
    Thromb Haemost (2011) 106, 90-101. PubMed  Europe PubMed DOI
  63. Valls Seron,M., Plug,T., Marquart,J.A., Marx,P.F., Herwald,H., DE Groot,P.G. and Meijers,J.C.
    Binding characteristics of thrombin-activatable fibrinolysis inhibitor to streptococcal surface collagen-like proteins A and B
    Thromb Haemost (2011) 106, 609-616. PubMed  Europe PubMed DOI
    64. 2010
  64. Buelens,K., Hassanzadeh-Ghassabeh,G., Muyldermans,S., Gils,A. and Declerck,P.J.
    Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor
    J Thromb Haemost (2010) 8, 1302-1312. PubMed  Europe PubMed DOI
  65. Heylen,E., Van Goethem,S., Willemse,J., Olsson,T., Augustyns,K. and Hendriks,D.
    Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasma
    Anal Biochem (2010) 396, 152-154. PubMed  Europe PubMed DOI  A
  66. Heylen,E., Van Goethem,S., Augustyns,K. and Hendriks,D.
    Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: challenges overcome by a novel selective assay
    Anal Biochem (2010) 403, 114-116. PubMed  Europe PubMed DOI  A
  67. Ieko,M., Yoshida,M., Naito,S., Nakabayashi,T., Kanazawa,K., Mizukami,K., Mukai,M., Atsumi,T. and Koike,T.
    Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation
    Int J Hematol (2010) 91, 776-783. PubMed  Europe PubMed DOI
  68. Jessen,L.R., Wiinberg,B., Kjelgaard-Hansen,M., Jensen,A.L., Rozanski,E. and Kristensen,A.T.
    Thrombin-activatable fibrinolysis inhibitor activity in healthy and diseased dogs
    Vet Clin Pathol (2010) 39, 296-301. PubMed  Europe PubMed DOI
  69. Joanna,D. and Wojciech,W.
    The role of thrombin-activatable fibrinolysis inhibitor in the pathophysiology of hemostasis
    Adv Clin Exp Med (2010) 19, 379-387.
  70. Kozian,D.H., Lorenz,M., Marz,W., Cousin,E., Mace,S. and Deleuze,J.F.
    Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study
    Thromb Haemost (2010) 103, 976-983. PubMed  Europe PubMed DOI  M
  71. Kraft,P., Schwarz,T., Meijers,J.C., Stoll,G. and Kleinschnitz,C.
    Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke
    PLoS ONE (2010) 5, e11658-e11658. PubMed  Europe PubMed DOI  PMC  EPMC  K
  72. Miljic,P., Heylen,E., Willemse,J., Djordjevic,V., Radojkovic,D., Colovic,M., Elezovic,I. and Hendriks,D.
    Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis
    Srp Arh Celok Lek (2010) 138 Suppl 1, 74-78. PubMed  Europe PubMed
  73. Morser,J., Gabazza,E.C., Myles,T. and Leung,L.L.
    What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?
    J Thromb Haemost (2010) 8, 868-876. PubMed  Europe PubMed DOI  K
  74. Pruner,I., Djordjevic,V., Miljic,P., Kovac,M., Antonijevic,N., Rakicevic,L. and Radojkovic,D.
    +1040 C/T polymorphism in coding region of thrombin-activatable fibrinolysis inhibitor gene and the risk of idiopathic recurrent fetal loss
    Blood Coagul Fibrinolysis (2010) 21, 679-682. PubMed  Europe PubMed DOI  M
  75. Qin,L., D'Alessandro-Gabazza,C.N., Aoki,S., Gil-Bernabe,P., Yano,Y., Takagi,T., Boveda-Ruiz,D., Ramirez Marmol,A.Y., San Martin Montenegro,V.T., Toda,M., Miyake,Y., Taguchi,O., Takei,Y., Morser,J. and Gabazza,E.C.
    Pulmonary hypertension is ameliorated in mice deficient in thrombin-activatable fibrinolysis inhibitor
    J Thromb Haemost (2010) 8, 808-816. PubMed  Europe PubMed DOI  K
  76. Sanglas,L., Arolas,J.L., Valnickova,Z., Aviles,F.X., Enghild,J.J. and Gomis-Ruth,F.X.
    Insights into the molecular inactivation mechanism of human activated thrombin-activatable fibrinolysis inhibitor
    J Thromb Haemost (2010) 8, 1056-1065. PubMed  Europe PubMed DOI
  77. Schultz,G., Tedesco,M.M., Sho,E., Nishimura,T., Sharif,S., Du,X., Myles,T., Morser,J., Dalman,R.L. and Leung,L.L.
    Enhanced abdominal aortic aneurysm formation in thrombin-activatable procarboxypeptidase B-deficient mice
    Arterioscler Thromb Vasc Biol (2010) 30, 1363-1370. PubMed  Europe PubMed DOI  K
  78. Valls Seron,M., Haiko,J., DE Groot,P.G., Korhonen,T.K. and Meijers,J.C.
    Thrombin-activatable fibrinolysis inhibitor is degraded by Salmonella enterica and Yersinia pestis
    J Thromb Haemost (2010) 8, 2232-2240. PubMed  Europe PubMed DOI
  79. Valnickova,Z., Sanglas,L., Arolas,J.L., Petersen,S.V., Schar,C., Otzen,D., Aviles,F.X., Gomis-Ruth,F.X. and Enghild,J.J.
    Flexibility of the thrombin-activatable fibrinolysis inhibitor pro-domain enables productive binding of protein substrates
    J Biol Chem (2010) 285, 38243-38250. PubMed  Europe PubMed DOI  S
    80. 2009
  80. Brouns,R., Heylen,E., Sheorajpanday,R., Willemse,J.L., Kunnen,J., De Surgeloose,D., Hendriks,D.F. and De Deyn,P.P.
    Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients
    Clin Neurol Neurosurg (2009) 111, 165-170. PubMed  Europe PubMed DOI
  81. de Bruijne,E.L., Gils,A., Guimaraes,A.H., Dippel,D.W., Deckers,J.W., van den Meiracker,A.H., Poldermans,D., Rijken,D.C., Declerck,P.J., de Maat,M.P. and Leebeek,F.W.
    The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study
    J Thromb Haemost (2009) 7, 919-927. PubMed  Europe PubMed DOI
  82. Dempfle,C.E. and Borggrefe,M.
    Thrombin-activatable fibrinolysis inhibitor-A inhibitors: drugs for sepsis or drugs for disseminated intravascular coagulation?
    Crit Care Med (2009) 37, 1823-1824. PubMed  Europe PubMed DOI  I
  83. Develter,J., Dewilde,M., Gils,A. and Declerck,P.J.
    Comparative study of inhibitory antibody derivatives towards thrombin activatable fibrinolysis inhibitor
    Thromb Haemost (2009) 102, 69-75. PubMed  Europe PubMed DOI
  84. Du,X.Y., Zabel,B.A., Myles,T., Allen,S.J., Handel,T.M., Lee,P.P., Butcher,E.C. and Leung,L.L.
    Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets
    J Biol Chem (2009) 284, 751-758. PubMed  Europe PubMed DOI  PMC  EPMC
  85. Marx,P.F., Plug,T., Havik,S.R., Morgelin,M. and Meijers,J.C.
    The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme?
    J Thromb Haemost (2009) 7, 445-452. PubMed  Europe PubMed DOI
  86. Marx,P.F., Verkleij,C.J., Seron,M.V. and Meijers,J.C.
    Recent developments in thrombin-activatable fibrinolysis inhibitor research
    Mini Rev Med Chem (2009) 9, 1165-1173. PubMed  Europe PubMed DOI  V
  87. Meltzer,M.E., Doggen,C.J., DE Groot,P.G., Meijers,J.C., Rosendaal,F.R. and Lisman,T.
    Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men
    Haematologica (2009) 94, 811-818. PubMed  Europe PubMed DOI  PMC  EPMC
  88. Miah,M.F. and Boffa,M.B.
    Functional analysis of mutant variants of thrombin-activatable fibrinolysis inhibitor resistant to activation by thrombin or plasmin
    J Thromb Haemost (2009) 7, 665-672. PubMed  Europe PubMed DOI
  89. Muto,Y., Suzuki,K., Iida,H., Sakakibara,S., Kato,E., Itoh,F., Kakui,N. and Ishii,H.
    EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats
    Crit Care Med (2009) 37, 1744-1749. PubMed  Europe PubMed DOI  I
  90. Okumura,N., Koh,T., Hasebe,Y., Seki,T. and Ariga,T.
    A novel function of thrombin-activatable fibrinolysis inhibitor during rat liver regeneration and in growth-promoted hepatocytes in primary culture
    J Biol Chem (2009) 284, 16553-16561. PubMed  Europe PubMed DOI  PMC  EPMC
  91. Sharif,S.A., Du,X., Myles,T., Song,J.J., Price,E., Lee,D.M., Goodman,S.B., Nagashima,M., Morser,J., Robinson,W.H. and Leung,L.L.
    Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis
    Arthritis Rheum (2009) 60, 2902-2912. PubMed  Europe PubMed DOI
  92. Tassies,D., Roque,M., Monteagudo,J., Martorell,T., Sionis,A., Arzamendi,D., Heras,M. and Reverter,J.C.
    Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome
    Thromb Res (2009) 124, 614-618. PubMed  Europe PubMed DOI  M
  93. Tregouet,D.A., Schnabel,R., Alessi,M.C., Godefroy,T., Declerck,P.J., Nicaud,V., Munzel,T., Bickel,C., Rupprecht,H.J., Lubos,E., Zeller,T., Juhan-Vague,I., Blankenberg,S., Tiret,L. and Morange,P.E.
    Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the Athero Gene study
    J Thromb Haemost (2009) 7, 49-57. PubMed  Europe PubMed DOI
  94. Valnickova,Z., Thaysen-Andersen,M., Hojrup,P., Christensen,T., Sanggaard,K.W., Kristensen,T. and Enghild,J.J.
    Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI)
    BMC Biochem (2009) 10, 13-13. PubMed  Europe PubMed DOI  PMC  EPMC
  95. Willemse,J.L., Heylen,E., Nesheim,M.E. and Hendriks,D.F.
    Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?
    J Thromb Haemost (2009) 7, 1962-1971. PubMed  Europe PubMed DOI  V
  96. Wu,C., Kim,P.Y., Manuel,R., Seto,M., Whitlow,M., Nagashima,M., Morser,J., Gils,A., Declerck,P. and Nesheim,M.E.
    The roles of selected arginine and lysine residues of TAFI (pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex
    J Biol Chem (2009) 284, 7059-7067. PubMed  Europe PubMed DOI  PMC  EPMC
    97. 2008
  97. Akinci,B. and Yesil,S.
    Role of thrombin activatable fibrinolysis inhibitor in endocrine and cardiovascular disorders
    Recent Pat Endocr Metab Immune Drug Discov (2008) 2, 57-61.
  98. Anand,K., Pallares,I., Valnickova,Z., Christensen,T., Vendrell,J., Wendt,K.U., Schreuder,H.A., Enghild,J.J. and Aviles,F.X.
    The crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) provides the structural basis for its intrinsic activity and the short half-life of TAFIa
    J Biol Chem (2008) 283, 29416-29423. PubMed  Europe PubMed DOI  PMC  EPMC  S
  99. Biscetti,F.
    Glycosylation of thrombin activatable fibrinolysis inhibitor: why is it so important?
    Circ Res (2008) 102, 278-279. PubMed  Europe PubMed DOI
  100. Biswas,A., Tiwari,A.K., Ranjan,R., Meena,A., Akhter,M.S., Yadav,B.K., Behari,M. and Saxena,R.
    Thrombin activatable fibrinolysis inhibitor gene polymorphisms are associated with antigenic levels in the Asian-Indian population but may not be a risk for stroke
    Br J Haematol (2008) 143, 581-588. PubMed  Europe PubMed DOI  M
  101. Boffa,M.B., Maret,D., Hamill,J.D., Bastajian,N., Crainich,P., Jenny,N.S., Tang,Z., Macy,E.M., Tracy,R.P., Franco,R.F., Nesheim,M.E. and Koschinsky,M.L.
    Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis
    Blood (2008) 111, 183-189. PubMed  Europe PubMed DOI  M
  102. Bruno,N.E., Yano,Y., Takei,Y., Qin,L., Suzuki,T., Morser,J., D'Alessandro-Gabazza,C.N., Mizoguchi,A., Suzuki,K., Taguchi,O., Gabazza,E.C. and Sumida,Y.
    Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency
    Thromb Haemost (2008) 100, 90-100. PubMed  Europe PubMed DOI  K
  103. Buelens,K., Hillmayer,K., Compernolle,G., Declerck,P.J. and Gils,A.
    Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitor
    Circ Res (2008) 102, 295-301. PubMed  Europe PubMed DOI
  104. Foley,J.H., Kim,P. and Nesheim,M.E.
    Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis
    J Biol Chem (2008) 283, 8863-8867. PubMed  Europe PubMed DOI  PMC  EPMC
  105. Gils,A.
    Which carboxypeptidase determines the antifibrinolytic potential?
    J Thromb Haemost (2008) 6, 846-847. PubMed  Europe PubMed DOI
  106. Hillmayer,K., Ceresa,E., Vancraenenbroeck,R., Declerck,P.J. and Gils,A.
    Conformational (in)stability of rat vs. human activated thrombin activatable fibrinolysis inhibitor
    J Thromb Haemost (2008) 6, 1426-1428. PubMed  Europe PubMed DOI
  107. Hillmayer,K., Vancraenenbroeck,R., De Maeyer,M., Compernolle,G., Declerck,P.J. and Gils,A.
    Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor
    J Thromb Haemost (2008) 6, 1892-1899. PubMed  Europe PubMed DOI  I
  108. Kim,P.Y., Foley,J., Hsu,G., Kim,P.Y. and Nesheim,M.E.
    An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma
    Anal Biochem (2008) 372, 32-40. PubMed  Europe PubMed DOI  A
  109. Kim,P.Y., Kim,P.Y., Hoogendorn,H., Giles,A.R. and Nesheim,M.E.
    Activated thrombin-activatable fibrinolysis inhibitor is generated in vivo at levels that can substantially affect fibrinolysis in chimpanzees in response to thrombin generation
    J Thromb Haemost (2008) 6, 1600-1602. PubMed  Europe PubMed DOI  PMC  EPMC
  110. Leung,L.L., Myles,T., Nishimura,T., Song,J.J. and Robinson,W.H.
    Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI)
    Mol Immunol (2008) 45, 4080-4083. PubMed  Europe PubMed DOI
  111. Marx,P.F., Brondijk,T.H., Plug,T., Romijn,R.A., Hemrika,W., Meijers,J.C. and Huizinga,E.G.
    Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation
    Blood (2008) 112, 2803-2809. PubMed  Europe PubMed DOI  S  I
  112. Matthiessen,H.P., Willemse,J., Weber,A., Turecek,P.L., Deiteren,K., Hendriks,D., Ehrlich,H.J. and Schwarz,H.P.
    Ethanol dependence of alpha1-antitrypsin C-terminal Lys truncation mediated by basic carboxypeptidases
    Transfusion (2008) 48, 314-320. PubMed  Europe PubMed DOI
  113. Sanglas,L., Valnickova,Z., Arolas,J.L., Pallares,I., Guevara,T., Sola,M., Kristensen,T., Enghild,J.J., Aviles,F.X. and Gomis-Ruth,F.X.
    Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis
    Mol Cell (2008) 31, 598-606. PubMed  Europe PubMed DOI  S
  114. Soni,H., Sharma,A., Bhatt,S., Jain,M.R. and Patel,P.R.
    Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats
    Pharmacology (2008) 82, 304-309. PubMed  Europe PubMed DOI
  115. Willemse,J.L., Polla,M., Olsson,T. and Hendriks,D.F.
    Comparative substrate specificity study of carboxypeptidase U (TAFIa) and carboxypeptidase N: development of highly selective CPU substrates as useful tools for assay development
    Clin Chim Acta (2008) 387, 158-160. PubMed  Europe PubMed DOI  A
  116. Willemse,J.L., Brouns,R., Heylen,E., De Deyn,P.P. and Hendriks,D.F.
    Carboxypeptidase U (TAFIa) activity is induced in vivo in ischemic stroke patients receiving thrombolytic therapy
    J Thromb Haemost (2008) 6, 200-202. PubMed  Europe PubMed DOI
  117. Xu,C.W., Wang,L.L., Wu,X.B., Zhao,J.J., Du,Y.M. and Jiang,C.Y.
    [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease]
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi (2008) 25, 438-442. PubMed  Europe PubMed  M
    118. 2007
  118. Akatsu,H., Ishiguro,M., Ogawa,N., Kanesaka,T., Okada,N., Yamamoto,T., Campbell,W. and Okada,H.
    Plasma levels of unactivated thrombin activatable fibrinolysis inhibitor (TAFI) are down-regulated in young adult women: analysis of a normal japanese population
    Microbiol Immunol (2007) 51, 507-517. PubMed  Europe PubMed
  119. Boffa,M.B. and Koschinsky,M.L.
    Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles
    Clin Biochem (2007) 40, 431-442. PubMed  Europe PubMed DOI  V
  120. Bunnage,M.E., Blagg,J., Steele,J., Owen,D.R., Allerton,C., McElroy,A.B., Miller,D., Ringer,T., Butcher,K., Beaumont,K., Evans,K., Gray,A.J., Holland,S.J., Feeder,N., Moore,R.S. and Brown,D.G.
    Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis
    J Med Chem (2007) 50, 6095-6103. PubMed  Europe PubMed DOI  I
  121. de Bruijne,E.L., Darwish Murad,S., de Maat,M.P., Tanck,M.W., Haagsma,E.B., van Hoek,B., Rosendaal,F.R., Janssen,H.L. and Leebeek,F.W.
    Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis
    Thromb Haemost (2007) 97, 181-185. PubMed  Europe PubMed DOI  M
  122. Dusse,L.M., Cooper,A.J. and Lwaleed,B.A.
    Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
    Clin Chim Acta (2007) 378, 1-6. PubMed  Europe PubMed DOI
  123. Guimaraes,A.H., Laurens,N., Weijers,E.M., Koolwijk,P., van Hinsbergh,V.W. and Rijken,D.C.
    TAFI and pancreatic carboxypeptidase B modulate in vitro capillary tube formation by human microvascular endothelial cells
    Arterioscler Thromb Vasc Biol (2007) 27, 2157-2162. PubMed  Europe PubMed DOI
  124. Islam,I., Bryant,J., May,K., Mohan,R., Yuan,S., Kent,L., Morser,J., Zhao,L., Vergona,R., White,K., Adler,M., Whitlow,M. and Buckman,B.O.
    3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa)
    Bioorg Med Chem Lett (2007) 17, 1349-1354. PubMed  Europe PubMed DOI  I
  125. Ladenvall,C., Gils,A., Jood,K., Blomstrand,C., Declerck,P.J. and Jern,C.
    Thrombin Activatable Fibrinolysis Inhibitor Activation Peptide Shows Association With All Major Subtypes of Ischemic Stroke and With TAFI Gene Variation
    Arterioscler Thromb Vasc Biol (2007) 27, 955-962. PubMed  Europe PubMed DOI
  126. Muto,Y., Suzuki,K., Iida,H. and Ishii,H.
    EF6265, a novel plasma carboxypeptidase B inhibitor, protects against renal dysfunction in rat thrombotic glomerulonephritis through enhancing fibrinolysis
    Nephron Exp Nephrol (2007) 106, e113-e121. PubMed  Europe PubMed DOI  I
  127. Nishimura,T., Myles,T., Piliposky,A.M., Kao,P.N., Berry,G.J. and Leung,L.L.
    Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo
    Blood (2007) 109, 1992-1997. PubMed  Europe PubMed DOI  PMC  EPMC
  128. Skeppholm,M., Wallen,N.H., Malmqvist,K., Kallner,A. and Antovic,J.P.
    Comparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndrome
    Thromb Res (2007) 121, 175-181. PubMed  Europe PubMed DOI  A
  129. Vairaktaris,E., Yapijakis,C., Nkenke,E., Vassiliou,S., Vylliotis,A., Nixon,A.M., Derka,S., Ragos,V., Spyridonidou,S., Tsigris,C., Neukam,F.W. and Patsouris,E.
    The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer
    Am J Hematol (2007) 82, 1010-1012. PubMed  Europe PubMed DOI  M
  130. Valnickova,Z., Thogersen,I.B., Potempa,J. and Enghild,J.J.
    Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase
    J Biol Chem (2007) 282, 3066-3076. PubMed  Europe PubMed DOI
  131. Valnickova,Z., Thogersen,I.B., Potempa,J. and Enghild,J.J.
    The intrinsic enzymatic activity of procarboxypeptidase U (TAFI) does not significantly influence the fibrinolytic rate: reply to a rebuttal
    J Thromb Haemost (2007) 5, 1336-1337. PubMed  Europe PubMed DOI
  132. Walker,J.B. and Bajzar,L.
    Complete inhibition of fibrinolysis by sustained carboxypeptidase B activity: the role and requirement of plasmin inhibitors
    J Thromb Haemost (2007) 5, 1257-1264. PubMed  Europe PubMed DOI
  133. Wang,X., Smith,P.L., Hsu,M.Y., Tamasi,J.A., Bird,E. and Schumacher,W.A.
    Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis
    J Thromb Thrombolysis (2007) 23, 41-49. PubMed  Europe PubMed DOI  K
  134. Wang,Y.X., da Cunha,V., Vincelette,J., Zhao,L., Nagashima,M., Kawai,K., Yuan,S., Emayan,K., Islam,I., Hosoya,J., Sullivan,M.E., Dole,W.P., Morser,J., Buckman,B.O. and Vergona,R.
    A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis
    Thromb Haemost (2007) 97, 54-61. PubMed  Europe PubMed DOI  I
  135. Wang,Y.X., Zhao,L., Nagashima,M., Vincelette,J., Sukovich,D., Li,W., Subramanyam,B., Yuan,S., Emayan,K., Islam,I., Hrvatin,P., Bryant,J., Light,D.R., Vergona,R., Morser,J. and Buckman,B.O.
    A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) - part I: pharmacological characterization
    Thromb Haemost (2007) 97, 45-53. PubMed  Europe PubMed DOI  I
  136. Willemse,J.L., Matus,V., Heylen,E., Mezzano,D. and Hendriks,D.F.
    Influence of the Thr325Ile polymorphism on procarboxypeptidase U (thrombin-activable fibrinolysis inhibitor) activity-based assays
    J Thromb Haemost (2007) 5, 872-875. PubMed  Europe PubMed DOI  A  M
  137. Willemse,J.L., Heylen,E. and Hendriks,D.F.
    The intrinsic enzymatic activity of procarboxypeptidase U (TAFI) does not significantly influence the fibrinolysis rate: a rebuttal
    J Thromb Haemost (2007) 5, 1334-1336. PubMed  Europe PubMed DOI
    138. 2006
  138. Bertina,R.M., van Tilburg,N.H., Haverkate,F., Bouma,B.N., von dem Borne,P.A., Meijers,J.C., Campbell,W., Eaton,D., Hendriks,D.F. and Willemse,J.L.
    Discovery of thrombin activatable fibrinolysis inhibitor (TAFI)
    J Thromb Haemost (2006) 4, 256-257. PubMed  Europe PubMed DOI
  139. Bouma,B.N. and Mosnier,L.O.
    Thrombin activatable fibrinolysis inhibitor (TAFI) - how does thrombin regulate fibrinolysis?
    Ann Med (2006) 38, 378-388. PubMed  Europe PubMed DOI  V
  140. [YEAR:4-4-2006]Ceresa,E., Van de Borne,K., Peeters,M., Lijnen,H.R., Declerck,P.J. and Gils,A.
    Generation of a stable activated thrombin activable fibrinolysis inhibitor variant
    J Biol Chem (4-4-2006) 281, 15878-15883. PubMed  Europe PubMed DOI
  141. Fujimoto,H., Gabazza,E.C., Taguchi,O., Nishii,Y., Nakahara,H., Bruno,N.E., D'Alessandro-Gabazza,C.N., Kasper,M., Yano,Y., Nagashima,M., Morser,J., Broze,G.J., Suzuki,K. and Adachi,Y.
    Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis
    Am J Pathol (2006) 168, 1086-1096. PubMed  Europe PubMed DOI  PMC  EPMC  K
  142. Hillmayer,K., Macovei,A., Pauwels,D., Compernolle,G., Declerck,P.J. and Gils,A.
    Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI) - a comparative study assessing the biological equivalence of rat, murine and human TAFI
    J Thromb Haemost (2006) 4, 2470-2477. PubMed  Europe PubMed DOI
  143. Martini,C.H., Brandts,A., de Bruijne,E.L., van Hylckama Vlieg,A., Leebeek,F.W., Lisman,T. and Rosendaal,F.R.
    The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis
    Br J Haematol (2006) 134, 92-94. PubMed  Europe PubMed DOI  M
  144. [YEAR:7-9-2006]Mosnier,L.O. and Bouma,B.N.
    Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis
    Arterioscler Thromb Vasc Biol (7-9-2006) 26, 2445-2453. PubMed  Europe PubMed DOI  V
  145. [YEAR:7-2-2006]Valnickova,Z., Christensen,T., Skottrup,P., Thogersen,I.B., Hojrup,P. and Enghild,J.J.
    Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): evidence for a large shift in the isoelectric point and reduced solubility upon activation
    Biochemistry (7-2-2006) 45, 1525-1535. PubMed  Europe PubMed DOI
  146. Willemse,J.L. and Hendriks,D.F.
    Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge
    Clin Chem (2006) 52, 30-36. PubMed  Europe PubMed DOI
    147. 2005
  147. Cruden,N.L., Lawes,L., Masson,P., Robinson,S.D., Ludlam,C.A. and Newby,D.E.
    Inhibition of thrombin activatable fibrinolysis inhibitor augments fibrinolysis in human whole blood
    J Thromb Haemost (2005) 3, 2351-2353. PubMed  Europe PubMed DOI
  148. Do,Y.H., Gifford-Moore,D.S., Beight,D.W., Rathnachalam,R., Klimkowski,V.J., Warshawsky,A.M. and Lu,D.
    Inhibition of thrombin activatable fibrinolysis inhibitor by cysteine derivatives
    Thromb Res (2005) 116, 265-271. PubMed  Europe PubMed DOI  I
  149. Frere,C., Morange,P.E., Saut,N., Tregouet,D.A., Grosley,M., Beltran,J., Juhan-Vague,I. and Alessi,M.C.
    Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact
    Thromb Haemost (2005) 94, 373-379. PubMed  Europe PubMed DOI
  150. Guimaraes,A.H., Bertina,R.M. and Rijken,D.C.
    A new functional assay of thrombin activatable fibrinolysis inhibitor
    J Thromb Haemost (2005) 3, 1284-1292. PubMed  Europe PubMed DOI  A
  151. He,L., Asai,S., Kawamura,T., Kimbara,N., Tada,T., Okada,H. and Okada,N.
    Hepatitis induced by an IgM monoclonal antibody against procarboxypeptidase R
    Microbiol Immunol (2005) 49, 373-380. PubMed  Europe PubMed
  152. [YEAR:8-7-2005]Leebeek,F.W., Goor,M.P., Guimaraes,A.H., Brouwers,G.J., Maat,M.P., Dippel,D.W. and Rijken,D.C.
    High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke
    J Thromb Haemost (8-7-2005) 3, 2211-2218. PubMed  Europe PubMed DOI
  153. Mao,S.S., Holahan,M.A., Bailey,C., Wu,G., Colussi,D., Carroll,S.S. and Cook,J.J.
    Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice
    Blood Coagul Fibrinolysis (2005) 16, 407-415. PubMed  Europe PubMed  K
  154. Marx,P.F., Havik,S.R., Bouma,B.N. and Meijers,J.C.
    Role of isoleucine residues 182 and 183 in thrombin-activatable fibrinolysis inhibitor
    J Thromb Haemost (2005) 3, 1293-1300. PubMed  Europe PubMed DOI
  155. Nesheim,M. and Bajzar,L.
    The discovery of TAFI
    J Thromb Haemost (2005) 3, 2139-2146. PubMed  Europe PubMed DOI
  156. Post,M.S., Leurs,J.R., Van der Mooren,M.J., Van Baal,W.M., Hendriks,D.F., Stehouwer,C.D. and Kenemans,P.
    Different effects of low-dose transdermal and oral oestrogen therapy on procarboxy-peptidase U, an inhibitor of fibrinolysis, in healthy postmenopausal women: a randomised, placebo-controlled study
    Thromb Haemost (2005) 93, 620-622. PubMed  Europe PubMed DOI
  157. [YEAR:15-11-2005]Renckens,R., Roelofs,J.J., ter Horst,S.A., van 't Veer,C., Havik,S.R., Florquin,S., Wagenaar,G.T., Meijers,J.C. and van der Poll,T.
    Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice
    J Immunol (15-11-2005) 175, 6764-6771. PubMed  Europe PubMed  K
  158. Zimonjic,D.B., Liu,J., Xu,W.H., Zhou,X., Popescu,N.C. and Shi,G.P.
    Assignment of murine placental cathepsin R to mouse chromosome bands 13B2-B3 by fluorescence in situ hybridization
    Cytogenet Genome Res (2005) 111, 96-96. PubMed  Europe PubMed DOI
    159. 2004
  159. Akatsu,H., Yamagata,H., Chen,Y., Miki,T., Kamino,K., Takeda,M., Campbell,W., Kondo,I., Kosaka,K., Yamamoto,T. and Okada,H.
    TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction
    Br J Haematol (2004) 127, 440-447. PubMed  Europe PubMed DOI  M
  160. Antovic,J.P., Schulman,S., An,S.S., Greenfield,R.S. and Blomback,M.
    Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
    Scand J Clin Lab Invest (2004) 64, 745-751. PubMed  Europe PubMed DOI
  161. [YEAR:1-10-2004]Asai,S., Sato,T., Tada,T., Miyamoto,T., Kimbara,N., Motoyama,N., Okada,H. and Okada,N.
    Absence of procarboxypeptidase R induces complement-mediated lethal inflammation in lipopolysaccharide-primed mice
    J Immunol (1-10-2004) 173, 4669-4674. PubMed  Europe PubMed  K
  162. Bajzar,L., Jain,N., Wang,P. and Walker,J.B.
    Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis
    Crit Care Med (2004) 32, S320-S324. PubMed  Europe PubMed
  163. Bouma,B.N. and Meijers,J.C.
    New insights into factors affecting clot stability: a role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R)
    Semin Hematol (2004) 41, 13-19. PubMed  Europe PubMed
  164. Guimaraes,A.H. and Rijken,D.C.
    Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model
    Thromb Haemost (2004) 91, 473-479. PubMed  Europe PubMed DOI
  165. Guimaraes,A.H., Barrett-Bergshoeff,M.M., Gils,A., Declerck,P.J. and Rijken,D.C.
    Migration of the activation peptide of thrombin-activatable fibrinolysis inhibitor (TAFI) during SDS-polyacrylamide gel electrophoresis
    J Thromb Haemost (2004) 2, 780-784. PubMed  Europe PubMed DOI
  166. Hendriks,D.F.
    Carboxypeptidase U
    [ISSN:0-12-079610-4] (2004) 2, 825-828.  V
  167. Kremer Hovinga,J.A., Franco,R.F., Zago,M.A., ten Cate,H., Westendorp,R.G. and Reitsma,P.H.
    A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease
    J Thromb Haemost (2004) 2, 54-57. PubMed  Europe PubMed DOI  M
  168. Leurs,J., Nerme,V., Sim,Y. and Hendriks,D.
    Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism
    J Thromb Haemost (2004) 2, 416-423. PubMed  Europe PubMed DOI
  169. Malyszko,J., Malyszko,J.S., Hryszko,T. and Mysliwiec,M.
    Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy
    Thromb Haemost (2004) 91, 480-486. PubMed  Europe PubMed DOI
  170. Maret,D., Boffa,M.B., Brien,D.F., Nesheim,M.E. and Koschinsky,M.L.
    Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor
    J Thromb Haemost (2004) 2, 1969-1979. PubMed  Europe PubMed DOI
  171. Marx,P.F.
    Thrombin-activatable fibrinolysis inhibitor
    Curr Med Chem (2004) 11, 2335-2348. PubMed  Europe PubMed  V
  172. [YEAR:20-2-2004]Marx,P.F., Havik,S.R., Marquart,J.A., Bouma,B.N. and Meijers,J.C.
    Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor
    J Biol Chem (20-2-2004) 279, 6620-6628. PubMed  Europe PubMed DOI
  173. Mousa,H.A., Downey,C., Alfirevic,Z. and Toh,C.H.
    Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy
    Thromb Haemost (2004) 92, 1025-1031. PubMed  Europe PubMed DOI
  174. [YEAR:3-5-2004]Nantermet,P.G., Barrow,J.C., Lindsley,S.R., Young,M., Mao,S.S., Carroll,S., Bailey,C., Bosserman,M., Colussi,D., McMasters,D.R., Vacca,J.P. and Selnick,H.G.
    Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P(1)(') group
    Bioorg Med Chem Lett (3-5-2004) 14, 2141-2145. PubMed  Europe PubMed DOI
  175. [YEAR:15-7-2004]Neill,E.K., Stewart,R.J., Schneider,M.M. and Nesheim,M.E.
    A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma
    Anal Biochem (15-7-2004) 330, 332-341. PubMed  Europe PubMed DOI  A
  176. Reijerkerk,A., Meijers,J.C., Havik,S.R., Bouma,B.N., Voest,E.E. and Gebbink,M.F.
    Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice
    J Thromb Haemost (2004) 2, 769-779. PubMed  Europe PubMed DOI  K
  177. [YEAR:8-1-2004]Schneider,M., Brufatto,N., Neill,E. and Nesheim,M.
    Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin
    J Biol Chem (8-1-2004) 279, 13340-13345. PubMed  Europe PubMed DOI
  178. Stromqvist,M., Hansson,L., Andersson,J.O., Johansson,T., Edlund,M., Enoksson,M., Goossens,F., Scharpe,S. and Hendriks,D.
    Properties of recombinant human plasma procarboxypeptidase U produced in mammalian and insect cells
    Clin Chim Acta (2004) 347, 49-59. PubMed  Europe PubMed DOI  E
  179. Suzuki,K., Muto,Y., Fushihara,K., Kanemoto,K., Iida,H., Sato,E., Kikuchi,C., Matsushima,T., Kato,E., Nomoto,M., Yoshioka,S. and Ishii,H.
    Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxypho sphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B
    J Pharmacol Exp Ther (2004) 309, 607-615. PubMed  Europe PubMed DOI
  180. [YEAR:2-7-2004]Walker,J.B. and Bajzar,L.
    The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability
    J Biol Chem (2-7-2004) 279, 27896-27904. PubMed  Europe PubMed DOI
    181. 2003
  181. Antovic,J.P. and Antovic,A.
    Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay
    Thromb Haemost (2003) 90, 620-627. PubMed  Europe PubMed DOI
  182. [YEAR:4-12-2003]Barrow,J.C., Nantermet,P.G., Stauffer,S.R., Ngo,P.L., Steinbeiser,M.A., Mao,S.S., Carroll,S.S., Bailey,C., Colussi,D., Bosserman,M., Burlein,C., Cook,J.J., Sitko,G., Tiller,P.R., Miller-Stein,C.M., Rose,M., McMasters,D.R., Vacca,J.P. and Selnick,H.G.
    Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics
    J Med Chem (4-12-2003) 46, 5294-5297. PubMed  Europe PubMed DOI
  183. [YEAR:20-9-2003]Bouma,B.N. and Mosnier,L.O.
    Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis
    Pathophysiol Haemost Thromb (20-9-2003) 33, 375-381. PubMed  Europe PubMed DOI  V
  184. Brouwers,G.J., Leebeek,F.W., Tanck,M.W., Wouter Jukema,J., Kluft,C. and de Maat,M.P.
    Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris
    Thromb Haemost (2003) 90, 92-100. PubMed  Europe PubMed DOI  M
  185. Colucci,M., Binetti,B.M., Branca,M.G., Clerici,C., Morelli,A., Semeraro,N. and Gresele,P.
    Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis
    Hepatology (2003) 38, 230-237. PubMed  Europe PubMed DOI
  186. Falk,K., Bjorquist,P., Falk,P., Hedgren,M., Ivarsson,M.L., Lanne,B., Panfilov,O. and Holmdahl,L.
    Antifibrinolytic proCPU is present in the peritoneal cavity during surgery
    Scand J Clin Lab Invest (2003) 63, 287-296. PubMed  Europe PubMed DOI
  187. [YEAR:15-6-2003]Fujimoto,H., Gabazza,E.C., Hataji,O., Yuda,H., D'Alessandro-Gabazza,C.N., Nakano,M., Franco,O.E., Hayashi,T., Suzuki,K., Adachi,Y. and Taguchi,O.
    Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease
    Am J Respir Crit Care Med (15-6-2003) 167, 1687-1694. PubMed  Europe PubMed DOI
  188. Knoefler,R., Ludwig,K., Kostka,H., Kuhlisch,E., Siegert,G. and Suttorp,M.
    The impact of single nucleotide polymorphisms of the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI antigen levels in healthy children and pediatric oncology patients
    Semin Thromb Hemost (2003) 29, 575-583. PubMed  Europe PubMed DOI  M
  189. Leurs,J., Wissing,B.M., Nerme,V., Schatteman,K., Bjorquist,P. and Hendriks,D.
    Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma
    Thromb Haemost (2003) 89, 264-271. PubMed  Europe PubMed DOI
  190. [YEAR:15-6-2003]Mosnier,L.O., Buijtenhuijs,P., Marx,P.F., Meijers,J.C. and Bouma,B.N.
    Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets
    Blood (15-6-2003) 101, 4844-4846. PubMed  Europe PubMed DOI
  191. [YEAR:14-2-2003]Muto,Y., Suzuki,K., Sato,E. and Ishii,H.
    Carboxypeptidase B inhibitors reduce tissue factor-induced renal microthrombi in rats
    Eur J Pharmacol (14-2-2003) 461, 181-189. PubMed  Europe PubMed DOI  I
  192. [YEAR:19-12-2003]Myles,T., Nishimura,T., Yun,T.H., Nagashima,M., Morser,J., Patterson,A.J., Pearl,R.G. and Leung,L.L.
    Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation
    J Biol Chem (19-12-2003) 278, 51059-51067. PubMed  Europe PubMed DOI
  193. Shimomura,Y., Kawamura,T., Komura,H., Campbell,W., Okada,N. and Okada,H.
    Modulation of procarboxypeptidase R (ProCPR) activation by complementary peptides to thrombomodulin
    Microbiol Immunol (2003) 47, 241-245. PubMed  Europe PubMed
  194. Toh,C.H.
    Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction
    Blood Coagul Fibrinolysis (2003) 14 Suppl 1, S69-S71. PubMed  Europe PubMed DOI
  195. [YEAR:14-3-2003]Walker,J.B., Hughes,B., James,I., Haddock,P., Kluft,C. and Bajzar,L.
    Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro
    J Biol Chem (14-3-2003) 278, 8913-8921. PubMed  Europe PubMed DOI  I
  196. Wu,C., Dong,N., da Cunha,V., Martin-McNulty,B., Tran,K., Nagashima,M., Wu,Q., Morser,J. and Wang,Y.X.
    Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs
    Thromb Haemost (2003) 90, 414-421. PubMed  Europe PubMed DOI
  197. [YEAR:22-8-2003]Zhao,L., Buckman,B., Seto,M., Morser,J. and Nagashima,M.
    Mutations in the substrate binding site of thrombin-activatable fibrinolysis inhibitor (TAFI) alter its substrate specificity
    J Biol Chem (22-8-2003) 278, 32359-32366. PubMed  Europe PubMed DOI
    198. 2002
  198. Antovic,J.P., Rafik Hamad,R., Antovic,A., Blomback,M. and Bremme,K.
    Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?
    Thromb Haemost (2002) 88, 644-647. PubMed  Europe PubMed DOI
  199. [YEAR:16-8-2002]Barbosa Pereira,P.J., Segura-Martin,S., Oliva,B., Ferrer-Orta,C., Aviles,F.X., Coll,M., Gomis-Ruth,F.X. and Vendrell,J.
    Human procarboxypeptidase B: three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI)
    J Mol Biol (16-8-2002) 321, 537-547. PubMed  Europe PubMed DOI  S
  200. Campbell,W.D., Lazoura,E., Okada,N. and Okada,H.
    Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N
    Microbiol Immunol (2002) 46, 131-134. PubMed  Europe PubMed
  201. Colucci,M., Pentimone,A., Binetti,B.M., Cramarossa,M., Piro,D. and Semeraro,N.
    Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin
    Thromb Haemost (2002) 88, 282-287. PubMed  Europe PubMed
  202. Kawamura,T., Okada,N. and Okada,H.
    Elastase from activated human neutrophils activates procarboxypeptidase R
    Microbiol Immunol (2002) 46, 225-230. PubMed  Europe PubMed
  203. Komura,H., Obata,K., Campbell,W., Yumoto,M., Shimomura,Y., Katsuya,H., Okada,N. and Okada,H.
    Effect of anticoagulants in colorimetric assay for basic carboxypeptidases
    Microbiol Immunol (2002) 46, 115-117. PubMed  Europe PubMed  A
  204. Komura,H., Shimomura,Y., Yumoto,M., Katsuya,H., Okada,N. and Okada,H.
    Heat stability of carboxypeptidase R of experimental animals
    Microbiol Immunol (2002) 46, 217-223. PubMed  Europe PubMed
  205. [YEAR:29-1-2002]Marx,P.F., Bouma,B.N. and Meijers,J.C.
    Role of zinc ions in activation and inactivation of thrombin-activatable fibrinolysis inhibitor
    Biochemistry (29-1-2002) 41, 1211-1216. PubMed  Europe PubMed DOI
  206. [YEAR:28-5-2002]Marx,P.F., Dawson,P.E., Bouma,B.N. and Meijers,J.C.
    Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor
    Biochemistry (28-5-2002) 41, 6688-6696. PubMed  Europe PubMed DOI
  207. Post,M.S., Hendriks,D.F., Van der Mooren,M.J., Van Baal,W.M., Leurs,J.R., Emeis,J.J., Kenemans,P. and Stehouwer,C.D.
    Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo-controlled, 12-week study in early postmenopausal women
    J Intern Med (2002) 251, 245-251. PubMed  Europe PubMed DOI
  208. [YEAR:22-3-2002]Schneider,M., Nagashima,M., Knappe,S., Zhao,L., Morser,J. and Nesheim,M.
    Amino acid residues in the P6-P'3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation
    J Biol Chem (22-3-2002) 277, 9944-9951. PubMed  Europe PubMed DOI
  209. Schneider,M., Boffa,M., Stewart,R., Rahman,M., Koschinsky,M. and Nesheim,M.
    Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme
    J Biol Chem (2002) 277, 1021-1030. PubMed  Europe PubMed DOI  M
  210. Swaisgood,C.M., Schmitt,D., Eaton,D. and Plow,E.F.
    In vivo regulation of plasminogen function by plasma carboxypeptidase B
    J Clin Invest (2002) 110, 1275-1282. PubMed  Europe PubMed DOI  PMC  EPMC  K
    211. 2001
  211. [YEAR:1-3-2001]Bouma,B.N., Marx,P.F., Mosnier,L.O. and Meijers,J.C.M.
    Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)
    Thromb Res (1-3-2001) 101, 329-354. PubMed  Europe PubMed DOI
  212. [YEAR:15-9-2001]Brouwers,G.J., Vos,H.L., Leebeek,F.W.G., Bulk,S., Schneider,M., Boffa,M., Koschinsky,M., van Tilburg,N.H., Nesheim,M.E., Bertina,R.M. and Garcia,E.B.G.
    A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels
    Blood (15-9-2001) 98, 1992-1993. PubMed  Europe PubMed DOI  M
  213. Campbell,W., Okada,N. and Okada,H.
    Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis
    Immunol Rev (2001) 180, 162-167. PubMed  Europe PubMed DOI
  214. Colucci,M., D'Aprile,A.M., Italia,A., Gresele,P., Morser,J. and Semeraro,N.
    Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA
    Thromb Haemost (2001) 85, 661-666. PubMed  Europe PubMed
  215. Henry,M., Aubert,H., Morange,P.E., Nanni,I., Alessi,M.C., Tiret,L. and Juhan-Vague,I.
    Identification of polymorphisms in the promoter and the 3 ' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled
    Blood (2001) 97, 2053-2058. PubMed  Europe PubMed DOI  M
  216. Koschinsky,M.L., Boffa,M.B., Nesheim,M.E., Zinman,B., Hanley,A.J.G., Harris,S.B., Cao,H. and Hegele,R.A.
    Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activable fibrinolysis inhibitor (TAFI) with blood pressure
    Clin Genet (2001) 60, 345-349. PubMed  Europe PubMed DOI  M
  217. Matsumoto,A., Motozaki,K., Seki,T., Sasaki,R. and Kawabe,T.
    Expression of human brain carboxypeptidase B, a possible cleaving enzyme for beta-amyloid precursor protein, in peripheral fluids
    Neurosci Res (2001) 39, 313-317. PubMed  Europe PubMed DOI
  218. Matsumoto,A., Itoh,K., Seki,T., Motozaki,K. and Matsuyama,S.
    Human brain carboxypeptidase B, which cleaves beta-amyloid peptides in vitro, is expressed in the endoplasmic reticulum of neurons
    Eur J Neurosci (2001) 13, 1653-1657. PubMed  Europe PubMed DOI
  219. Mosnier,L.O., Meijers,J.C. and Bouma,B.N.
    Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin
    Thromb Haemost (2001) 85, 5-11. PubMed  Europe PubMed
  220. Mosnier,L.O., Lisman,T., van den Berg,H.M., Nieuwenhuis,H.K., Meijers,J.C. and Bouma,B.N.
    The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration
    Thromb Haemost (2001) 86, 1035-1039. PubMed  Europe PubMed
  221. Mosnier,L.O., Meijers,J.C. and Bouma,B.N.
    The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis
    Thromb Haemost (2001) 86, 1040-1046. PubMed  Europe PubMed
  222. Mosnier,L.O., Elisen,M.G., Bouma,B.N. and Meijers,J.C.
    Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation
    Thromb Haemost (2001) 86, 1057-1064. PubMed  Europe PubMed
  223. Schatteman,K.A., Goossens,F.J., Leurs,J., Kasahara,Y., Scharpe,S.S. and Hendriks,D.F.
    Fast homogeneous assay for plasma procarboxypeptidase U
    Clin Chem Lab Med (2001) 39, 806-810. PubMed  Europe PubMed DOI  A
  224. Stromqvist,M., Schatteman,K., Leurs,J., Verkerk,R., Andersson,J.O., Johansson,T., Scharpe,S. and Hendriks,D.
    Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma
    Thromb Haemost (2001) 85, 12-17. PubMed  Europe PubMed  A
  225. Tregouet,D.A., Aubert,H., Henry,M., Morange,P., Visvikis,S., Juhan-Vague,I. and Tiret,L.
    Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms
    Hum Genet (2001) 109, 191-197. PubMed  Europe PubMed DOI  M
  226. van Gorp,E.C., Minnema,M.C., Suharti,C., Mairuhu,A.T., Brandjes,D.P., ten Cate,H., Hack,C.E. and Meijers,J.C.
    Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever
    Br J Haematol (2001) 113, 94-99. PubMed  Europe PubMed DOI
    227. 2000
  227. Bajzar,L.
    Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway
    Arterioscler Thromb Vasc Biol (2000) 20, 2511-2518. PubMed  Europe PubMed  V
  228. Chetaille,P., Alessi,M.C., Kouassi,D., Morange,P.E. and Juhan-Vague,I.
    Plasma TAFI antigen variations in healthy subjects
    Thromb Haemost (2000) 83, 902-905. PubMed  Europe PubMed
  229. Marx,P.F., Wagenaar,G.T., Reijerkerk,A., Tiekstra,M.J., van Rossum,A.G., Gebbink,M.F. and Meijers,J.C.
    Characterization of mouse thrombin-activatable fibrinolysis inhibitor
    Thromb Haemost (2000) 83, 297-303. PubMed  Europe PubMed
  230. [YEAR:28-4-2000]Marx,P.F., Hackeng,T.M., Dawson,P.E., Griffin,J.H., Meijers,J.C. and Bouma,B.N.
    Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage
    J Biol Chem (28-4-2000) 275, 12410-12415. PubMed  Europe PubMed DOI
  231. Matsumoto,A., Itoh,K. and Matsumoto,R.
    A novel carboxypeptidase B that processes native beta-amyloid precursor protein is present in human hippocampus
    Eur J Neurosci (2000) 12, 227-238. PubMed  Europe PubMed DOI
  232. Meijers,J.C., Oudijk,E.J., Mosnier,L.O., Bos,R., Bouma,B.N., Nieuwenhuis,H.K. and Fijnheer,R.
    Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia
    Br J Haematol (2000) 108, 518-523. PubMed  Europe PubMed DOI
  233. [YEAR:15-5-2000]Nagashima,M., Werner,M., Wang,M., Zhao,L., Light,D.R., Pagila,R., Morser,J. and Verhallen,P.
    An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model
    Thromb Res (15-5-2000) 98, 333-342. PubMed  Europe PubMed DOI
  234. [YEAR:15-7-2000]Sato,T., Miwa,T., Akatsu,H., Matsukawa,N., Obata,K., Okada,N., Campbell,W. and Okada,H.
    Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not
    J Immunol (15-7-2000) 165, 1053-1058. PubMed  Europe PubMed
  235. [YEAR:25-2-2000]Schatteman,K.A., Goossens,F.J., Scharpe,S.S. and Hendriks,D.F.
    Proteolytic activation of purified human procarboxypeptidase U
    Clin Chim Acta (25-2-2000) 292, 25-40. PubMed  Europe PubMed DOI
  236. Silveira,A., Schatteman,K., Goossens,F., Moor,E., Scharpe,S., Stromqvist,M., Hendriks,D. and Hamsten,A.
    Plasma procarboxypeptidase U in men with symptomatic coronary artery disease
    Thromb Haemost (2000) 84, 364-368. PubMed  Europe PubMed
  237. [YEAR:24-11-2000]Stewart,R.J., Fredenburgh,J.C., Rischke,J.A., Bajzar,L. and Weitz,J.I.
    Thrombin-activable fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing the affinity of (DD)E for tissue plasminogen activator. A potential mechanism for enhancing the fibrin specificity of tissue plasminogen activator
    J Biol Chem (24-11-2000) 275, 36612-36620. PubMed  Europe PubMed DOI
    238. 1999
  238. [YEAR:18-5-1999]Boffa,M.B., Reid,T.S., Joo,E., Nesheim,M.E. and Koschinsky,M.L.
    Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B)
    Biochemistry (18-5-1999) 38, 6547-6558. PubMed  Europe PubMed DOI
  239. Guo,X., Morioka,A., Kaneko,Y., Okada,N., Obata,K., Nomura,T., Campbell,W. and Okada,H.
    Arginine carboxypeptidase (CPR) in human plasma determined with sandwich ELISA
    Microbiol Immunol (1999) 43, 691-698. PubMed  Europe PubMed
  240. [YEAR:3-12-1999]Mao,S.S., Cooper,C.M., Wood,T., Shafer,J.A. and Gardell,S.J.
    Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans
    J Biol Chem (3-12-1999) 274, 35046-35052. PubMed  Europe PubMed DOI
  241. Schatteman,K.A., Goossens,F.J., Scharpe,S.S., Neels,H.M. and Hendriks,D.F.
    Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma
    Clin Chem (1999) 45, 807-813. PubMed  Europe PubMed  A
  242. Schatteman,K.A., Goossens,F.J., Scharpe,S.S. and Hendriks,D.F.
    Activation of plasma procarboxypeptidase U in different mammalian species points to a conserved pathway of inhibition of fibrinolysis
    Thromb Haemost (1999) 82, 1718-1721. PubMed  Europe PubMed
    243. 1998
  243. Bajzar,L., Nesheim,M., Morser,J. and Tracy,P.B.
    Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor
    J Biol Chem (1998) 273, 2792-2798. PubMed  Europe PubMed DOI
  244. [YEAR:23-1-1998]Boffa,M.B., Wang,W., Bajzar,L. and Nesheim,M.E.
    Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties
    J Biol Chem (23-1-1998) 273, 2127-2135. PubMed  Europe PubMed DOI  I
  245. Nesheim,M.
    Fibrinolysis and the plasma carboxypeptidase
    Curr Opin Hematol (1998) 5, 309-313. PubMed  Europe PubMed  V
  246. [YEAR:16-10-1998]Valnickova,Z. and Enghild,J.J.
    Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin
    J Biol Chem (16-10-1998) 273, 27220-27224. PubMed  Europe PubMed DOI
  247. [YEAR:16-10-1998]Wang,W., Boffa,M.B., Bajzar,L., Walker,J.B. and Nesheim,M.E.
    A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor
    J Biol Chem (16-10-1998) 273, 27176-27181. PubMed  Europe PubMed DOI
    248. 1997
  248. Nesheim,M., Wang,W., Boffa,M., Nagashima,M., Morser,J. and Bajzar,L.
    Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis
    Thromb Haemost (1997) 78, 386-391. PubMed  Europe PubMed
  249. Plow,E.F., Allampallam,K. and Redlitz,A.
    The plasma carboxypeptidases and the regulation of the plasminogen system
    Trend.Cardiovasc.Med. (1997) 7, 71-75. PubMed  Europe PubMed DOI
  250. Sakharov,D.V., Plow,E.F. and Rijken,D.C.
    On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B
    J Biol Chem (1997) 272, 14477-14482. PubMed  Europe PubMed DOI
    251. 1996
  251. Broze,G.J., Jr. and Higuchi,D.A.
    Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma
    Blood (1996) 88, 3815-3823. PubMed  Europe PubMed
  252. Broze,G.J., Jr.
    Thrombin-dependent inhibition of fibrinolysis
    Curr Opin Hematol (1996) 3, 390-394. PubMed  Europe PubMed
  253. Valnickova,Z., Thogersen,I.B., Christensen,S., Chu,C.T., Pizzo,S.V. and Enghild,J.J.
    Activated human plasma carboxypeptidase B is retained in the blood by binding to alpha2-macroglobulin and pregnancy zone protein
    J Biol Chem (1996) 271, 12937-12943. PubMed  Europe PubMed DOI
  254. Vanhoof,G., Wauters,J., Schatteman,K., Hendriks,D., Goossens,F., Bossuyt,P. and Scharpe,S.
    The gene for human carboxypeptidase U (CPU) - A proposed novel regulator of plasminogen activation - Maps to 13q14.11
    Genomics (1996) 38, 454-455. PubMed  Europe PubMed DOI
    255. 1995
  255. [YEAR:16-6-1995]Bajzar,L., Manuel,R. and Nesheim,M.E.
    Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor
    J Biol Chem (16-6-1995) 270, 14477-14484. PubMed  Europe PubMed DOI
  256. Redlitz,A., Tan,A.K., Eaton,D.L. and Plow,E.F.
    Plasma carboxypeptidases as regulators of the plasminogen system
    J Clin Invest (1995) 96, 2534-2538. PubMed  Europe PubMed DOI  PMC  EPMC
  257. Tan,A.K. and Eaton,D.L.
    Activation and characterization of procarboxypeptidase B from human plasma
    Biochemistry (1995) 34, 5811-5816. PubMed  Europe PubMed
    258. 1994
  258. Wang,W., Hendriks,D.F. and Scharpe,S.S.
    Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen
    J Biol Chem (1994) 269, 15937-15944. PubMed  Europe PubMed
    259. 1992
  259. Hendriks,D., Wang,W., Van Sande,M. and Scharpe,S.
    Human serum carboxypeptidase U: a new kininase?
    Agents Actions Suppl (1992) 38, 407-413. PubMed  Europe PubMed
  260. Tsai,S.P. and Drayna,D.
    The gene encoding human plasma carboxypeptidase B (CPB2) resides on chromosome 13
    Genomics (1992) 14, 549-550. PubMed  Europe PubMed DOI
    261. 1991
  261. Eaton,D.L., Malloy,B.E., Tsai,S.P., Henzel,W. and Drayna,D.
    Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma
    J Biol Chem (1991) 266, 21833-21838. PubMed  Europe PubMed
    262. 1990
  262. Hendriks,D., Wang,W., Scharpe,S., Lommaert,M.P. and Van Sande,M.
    Purification and characterization of a new arginine carboxypeptidase in human serum
    Biochim Biophys Acta (1990) 1034, 86-92. PubMed  Europe PubMed DOI  I
    263. 1989
  263. [YEAR:15-8-1989]Campbell,W. and Okada,H.
    An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits
    Biochem Biophys Res Commun (15-8-1989) 162, 933-939. PubMed  Europe PubMed
  264. Hendriks,D., Scharpe,S., Van Sande,M. and Lommaert,M.P.
    A labile enzyme in fresh human serum interferes with the assay of carboxypeptidase N
    Clin Chem (1989) 35, 177-177. PubMed  Europe PubMed
  265. Hendriks,D., Scharpe,S., Van Sande,M. and Lommaert,M.P.
    Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N
    J Clin Chem Clin Biochem (1989) 27, 277-285. PubMed  Europe PubMed
    266. 1988
  266. Hendriks,D., Soons,J., Scharpe,S., Wevers,R., Van Sande,M. and Holmquist,B.
    Identification of the carboxypeptidase responsible for the post-synthetic modification of creatine kinase in human serum
    Clin Chim Acta (1988) 172, 253-260. PubMed  Europe PubMed
    267. 1977
  267. [YEAR:1-5-1977]Marinkovic,D.V., Marinkovic,J.N., Erdos,E.G. and Robinson,C.J.
    Purification of carboxypeptidase B from human pancreas
    Biochem J (1-5-1977) 163, 253-260. PubMed  Europe PubMed  PMC  EPMC

feedback
Page created 8-September-2023

EMBL-EBI logo

© 2026 EBI
Terms of use